Subbiah Vivek
Sarah Cannon Research Institute, Nashville, Tennessee, USA.
Nat Commun. 2025 May 29;16(1):4972. doi: 10.1038/s41467-025-60369-1.
Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite nine FDA approvals, real-world implementation challenges persist. Progress depends on universal genomic testing, an oncogenomic-savvy workforce, innovative trials, updated regulations, and real-world evidence to maximize potential.
不依赖组织类型的癌症疗法有望通过靶向分子驱动因素彻底改变肿瘤学。斯莱奇等人对近30万个肿瘤的研究发现，21.5%的肿瘤具有不依赖组织类型的适应症。尽管有九项获得美国食品药品监督管理局（FDA）的批准，但现实世界中的实施挑战依然存在。进展取决于普遍的基因组检测、具备肿瘤基因组学知识的工作人员、创新试验、更新的法规以及真实世界证据，以最大限度地发挥其潜力。
